首页 > 最新文献

Journal of Clinical Pathology最新文献

英文 中文
Molecular confirmation that fibrocartilaginous dysplasia is a variant of fibrous dysplasia. 分子证实纤维软骨发育不良是纤维性发育不良的一种变体。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-08-17 DOI: 10.1136/jcp-2024-209626
Juan Zhou, Xuling Su, Dingjun Hu, Li Zhang, Chunyan Chen, Keyang Sun, Huizhen Zhang, Zhiyan Liu

Aims: Fibrocartilaginous dysplasia (FCD) is a subvariant of fibrous dysplasia (FD). This study aims to retrospectively elucidate the clinicopathological and separate genetic features of the cartilaginous and fibro-osseous components of FCD.

Methods: In total, 24 patients (14 men and 10 women) with FCD were included in our cohort. The diagnosis was confirmed morphologically and immunohistochemically, and genetic features were determined via Sanger sequencing.

Results: Five patients were polyostotic, and 19 were monostotic, predominantly concerning the femur. Radiography revealed a well-demarcated ground glass appearance with ring-like or scattered calcification. Histologically, the lesions were characterised by proliferative fibroblasts, immature woven bone and highly differentiated hyaline cartilage. The fibro-osseous components exhibited positive immunoreaction with SATB2 and a low Ki-67 proliferation index. The fibro-osseous and cartilaginous components shared mutations at codon 201 in exon 8 of the guanine nucleotide-binding protein/a-subunit (GNAS) gene, specifically CGT>CAT (p.R201H) in four patients and the wild-type isocitrate dehydrogenase (IDH)1/IDH2 gene. Telomerase reverse transcriptase (TERT) promoter mutations (C288T and C229G) occurred in both fibro-osseous and cartilaginous components in two patients.

Conclusions: FCD encompasses areas of conventional FD with additional cartilage. Importantly, the presence or absence of mutations in the GNAS gene and/or the TERT promoter is common between the fibro-osseous and cartilaginous components of the disease. These results further confirmed FCD as a variant of FD.

目的:纤维软骨发育不良(FCD)是纤维性发育不良(FD)的一个亚变型。本研究旨在回顾性地阐明FCD的软骨成分和纤维骨成分的临床病理特征和不同的遗传特征:我们的队列中共纳入了 24 名 FCD 患者(14 名男性和 10 名女性)。通过形态学和免疫组化确诊,并通过桑格测序确定遗传特征:结果:5 名患者为多畸形,19 名为单畸形,主要涉及股骨。放射学检查显示,病变呈分界清楚的磨玻璃样外观,伴有环状或散在钙化。从组织学角度看,病变的特征是纤维母细胞增生、未成熟的编织骨和高度分化的透明软骨。纤维骨成分与 SATB2 呈阳性免疫反应,Ki-67 增殖指数较低。纤维骨成分和软骨成分共享鸟嘌呤核苷酸结合蛋白/a-亚基(GNAS)基因第8外显子201密码子的突变,特别是4名患者的CGT>CAT(p.R201H)和野生型异柠檬酸脱氢酶(IDH)1/IDH2基因。两名患者的端粒酶逆转录酶(TERT)启动子突变(C288T和C229G)发生在纤维骨质和软骨成分中:结论:FCD包括传统FD区域和额外的软骨。重要的是,GNAS基因和/或TERT启动子突变的存在与否在该病的纤维骨和软骨成分中很常见。这些结果进一步证实了FCD是FD的一种变体。
{"title":"Molecular confirmation that fibrocartilaginous dysplasia is a variant of fibrous dysplasia.","authors":"Juan Zhou, Xuling Su, Dingjun Hu, Li Zhang, Chunyan Chen, Keyang Sun, Huizhen Zhang, Zhiyan Liu","doi":"10.1136/jcp-2024-209626","DOIUrl":"https://doi.org/10.1136/jcp-2024-209626","url":null,"abstract":"<p><strong>Aims: </strong>Fibrocartilaginous dysplasia (FCD) is a subvariant of fibrous dysplasia (FD). This study aims to retrospectively elucidate the clinicopathological and separate genetic features of the cartilaginous and fibro-osseous components of FCD.</p><p><strong>Methods: </strong>In total, 24 patients (14 men and 10 women) with FCD were included in our cohort. The diagnosis was confirmed morphologically and immunohistochemically, and genetic features were determined via Sanger sequencing.</p><p><strong>Results: </strong>Five patients were polyostotic, and 19 were monostotic, predominantly concerning the femur. Radiography revealed a well-demarcated ground glass appearance with ring-like or scattered calcification. Histologically, the lesions were characterised by proliferative fibroblasts, immature woven bone and highly differentiated hyaline cartilage. The fibro-osseous components exhibited positive immunoreaction with SATB2 and a low Ki-67 proliferation index. The fibro-osseous and cartilaginous components shared mutations at codon 201 in exon 8 of the guanine nucleotide-binding protein/a-subunit (<i>GNAS)</i> gene, specifically CGT>CAT (p.R201H) in four patients and the wild-type isocitrate dehydrogenase (<i>IDH)1/IDH2</i> gene. Telomerase reverse transcriptase (<i>TERT)</i> promoter mutations (C288T and C229G) occurred in both fibro-osseous and cartilaginous components in two patients.</p><p><strong>Conclusions: </strong>FCD encompasses areas of conventional FD with additional cartilage. Importantly, the presence or absence of mutations in the <i>GNAS</i> gene and/or the <i>TERT</i> promoter is common between the fibro-osseous and cartilaginous components of the disease. These results further confirmed FCD as a variant of FD.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NTRK gene alterations were enriched in hepatoid or enteroblastic differentiation type of gastric cancer. NTRK基因改变富集于肝样或肠样分化型胃癌。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-08-16 DOI: 10.1136/jcp-2023-208865
Xiaohong Pu, Yao Fu, Qi Sun, Lin Li, Attigah Kwasi, Ziyan Ma, Xiangshan Fan, Beicheng Sun

Aims Currently, the clinicopathological characteristics of gastric cancer (GC) with oncogenic NTRK alterations are not well known. Although NTRK fusion has been identified as prevalent in DNA mismatch repair protein deficient (dMMR) colorectal cancer (CRC), the relationship between NTRK alterations and dMMR protein expression in GC has not been previously explored.

Methods: Our study comprised 51 cases of EBV(Epstein-barr virus)-associated gastric carcinomas, 94 cases of dMMR GC, 90 cases of gastric adenocarcinoma with hepatoid or enteroblastic differentiation (GAHED) and 256 cases of conventional GC. Furthermore, to investigate the connection between NTRK fusion and dMMR proteins, we collected dMMR tumours of various types, including 21 cases of duodenal adenocarcinomas, 46 endometrioid carcinomas and 82 CRCs. NTRK fusion and amplification were screened in GC and various types of dMMR tumours using fluorescence in situ hybridisation (FISH), while cases positive for FISH translocation underwent next-generation sequencing testing.

Results: Our findings revealed the existence of two cases each of NTRK fusions and NTRK amplifications, which were all enriched in case of GAHED. Additionally, following an analysis of several types of cancers, we discovered that NTRK gene alterations were only present in dMMR CRC.

Conclusions: Our results indicate that NTRK gene alterations are not enriched in GC with dMMR but are specifically enriched in cases of GAHED.

目的 目前,对具有致癌 NTRK 改变的胃癌(GC)的临床病理特征还不甚了解。尽管NTRK融合在DNA错配修复蛋白缺乏(dMMR)的结直肠癌(CRC)中很常见,但NTRK改变与dMMR蛋白表达在GC中的关系此前尚未被探讨:我们的研究包括51例EBV(Epstein-barr病毒)相关胃癌、94例dMMR GC、90例肝样或肠样分化胃腺癌(GAHED)和256例常规GC。此外,为了研究 NTRK 融合与 dMMR 蛋白之间的联系,我们收集了不同类型的 dMMR 肿瘤,包括 21 例十二指肠腺癌、46 例子宫内膜样癌和 82 例 CRC。利用荧光原位杂交(FISH)技术筛查了GC和各类dMMR肿瘤的NTRK融合和扩增情况,同时对FISH易位阳性病例进行了新一代测序检测:结果:我们的研究结果显示,NTRK融合和NTRK扩增各存在两例,均在GAHED病例中富集。此外,在对几种癌症类型进行分析后,我们发现 NTRK 基因改变仅出现在 dMMR CRC 中:我们的研究结果表明,NTRK基因改变并不富集于dMMR的GC中,而是特别富集于GAHED病例中。
{"title":"NTRK gene alterations were enriched in hepatoid or enteroblastic differentiation type of gastric cancer.","authors":"Xiaohong Pu, Yao Fu, Qi Sun, Lin Li, Attigah Kwasi, Ziyan Ma, Xiangshan Fan, Beicheng Sun","doi":"10.1136/jcp-2023-208865","DOIUrl":"10.1136/jcp-2023-208865","url":null,"abstract":"<p><p><b>Aims</b> Currently, the clinicopathological characteristics of gastric cancer (GC) with oncogenic NTRK alterations are not well known. Although NTRK fusion has been identified as prevalent in DNA mismatch repair protein deficient (dMMR) colorectal cancer (CRC), the relationship between NTRK alterations and dMMR protein expression in GC has not been previously explored.</p><p><strong>Methods: </strong>Our study comprised 51 cases of EBV(Epstein-barr virus)-associated gastric carcinomas, 94 cases of dMMR GC, 90 cases of gastric adenocarcinoma with hepatoid or enteroblastic differentiation (GAHED) and 256 cases of conventional GC. Furthermore, to investigate the connection between NTRK fusion and dMMR proteins, we collected dMMR tumours of various types, including 21 cases of duodenal adenocarcinomas, 46 endometrioid carcinomas and 82 CRCs. NTRK fusion and amplification were screened in GC and various types of dMMR tumours using fluorescence in situ hybridisation (FISH), while cases positive for FISH translocation underwent next-generation sequencing testing.</p><p><strong>Results: </strong>Our findings revealed the existence of two cases each of NTRK fusions and NTRK amplifications, which were all enriched in case of GAHED. Additionally, following an analysis of several types of cancers, we discovered that NTRK gene alterations were only present in dMMR CRC.</p><p><strong>Conclusions: </strong>Our results indicate that NTRK gene alterations are not enriched in GC with dMMR but are specifically enriched in cases of GAHED.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"608-613"},"PeriodicalIF":2.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11474252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9841338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laboratory investigation of peritoneal fluids: an updated practical approach based on the available evidence. 腹腔液的实验室检查:基于现有证据的最新实用方法。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-08-16 DOI: 10.1136/jcp-2023-209282
Giulia Colombo, Elena Aloisio, Mauro Panteghini

Even though analysis of peritoneal fluids (PF) is often requested to medical laboratories for biochemical and morphological tests, there is still no mutual agreement on what the most appropriate way is to manage PF samples and which tests should be appropriately executed. In this update, we tried to identify the most useful tests for PF analysis to establish best practice indications. We performed a literature review and examined available guidelines to select the most appropriate tests by an evidence-based approach. Accordingly, the basic PF profile should include (1) serum to effusion albumin gradient and (2) automated cell counts with differential analysis. This profile allows to determine the PF nature, differentiating between 'high-albumin gradient' and 'low-albumin gradient' effusions, which helps to identify the pathophysiological process causing the ascites formation. Restricted to specific clinical situations, additional tests can be requested as follows: PF lactate dehydrogenase (LDH) and glucose, to exclude (LDH) or confirm (glucose) secondary bacterial peritonitis; PF total protein, to differentiate ascites of cardiac origin from other causes; PF (pancreatic) amylase, for the identification of pancreatic ascites; PF bilirubin, when a choleperitoneum is suspected; PF triglycerides, in differentiating chylous from pseudochylous ascites and PF creatinine, to detect intraperitoneal urinary leakage.

尽管人们经常要求医学实验室对腹腔液(PF)进行生化和形态学检验分析,但对于腹腔液样本的最适当管理方式以及应适当执行哪些检验,各方仍未达成一致意见。在本次更新中,我们试图找出对 PF 分析最有用的检验项目,以确定最佳实践指征。我们进行了文献综述并研究了现有指南,以循证方法选择最合适的测试。因此,PF 的基本特征应包括:(1)血清至渗出液白蛋白梯度;(2)自动细胞计数与差异分析。这种分析可以确定 PF 的性质,区分 "高白蛋白梯度 "和 "低白蛋白梯度 "渗出液,有助于确定导致腹水形成的病理生理过程。限于特定的临床情况,可要求进行以下附加检查:PF 乳酸脱氢酶(LDH)和葡萄糖,以排除(LDH)或确认(葡萄糖)继发性细菌性腹膜炎;PF 总蛋白,以区分心源性腹水和其他原因的腹水;PF(胰腺)淀粉酶,用于鉴别胰腺腹水;PF 胆红素,当怀疑有胆囊炎时;PF 甘油三酯,用于区分乳糜腹水和假性腹水;PF 肌酐,用于检测腹腔内漏尿。
{"title":"Laboratory investigation of peritoneal fluids: an updated practical approach based on the available evidence.","authors":"Giulia Colombo, Elena Aloisio, Mauro Panteghini","doi":"10.1136/jcp-2023-209282","DOIUrl":"10.1136/jcp-2023-209282","url":null,"abstract":"<p><p>Even though analysis of peritoneal fluids (PF) is often requested to medical laboratories for biochemical and morphological tests, there is still no mutual agreement on what the most appropriate way is to manage PF samples and which tests should be appropriately executed. In this update, we tried to identify the most useful tests for PF analysis to establish best practice indications. We performed a literature review and examined available guidelines to select the most appropriate tests by an evidence-based approach. Accordingly, the basic PF profile should include (1) serum to effusion albumin gradient and (2) automated cell counts with differential analysis. This profile allows to determine the PF nature, differentiating between 'high-albumin gradient' and 'low-albumin gradient' effusions, which helps to identify the pathophysiological process causing the ascites formation. Restricted to specific clinical situations, additional tests can be requested as follows: PF lactate dehydrogenase (LDH) and glucose, to exclude (LDH) or confirm (glucose) secondary bacterial peritonitis; PF total protein, to differentiate ascites of cardiac origin from other causes; PF (pancreatic) amylase, for the identification of pancreatic ascites; PF bilirubin, when a choleperitoneum is suspected; PF triglycerides, in differentiating chylous from pseudochylous ascites and PF creatinine, to detect intraperitoneal urinary leakage.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"579-585"},"PeriodicalIF":2.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autopsy findings from patients diagnosed with COVID-19 demonstrate unique morphological patterns in bone marrow and lymph node. 确诊为 COVID-19 的患者的尸检结果显示骨髓和淋巴结有独特的形态模式。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-08-16 DOI: 10.1136/jcp-2023-208875
Ali AlJabban, Mark G Evans, Geoffrey G Fell, Jack P Guccione, Robert A Edwards, Geraldine S Pinkus, Robert F Padera, Olga Pozdnyakova, Annette S Kim

Aims: The identification of haemophagocytosis in bone marrow (BM) is recurrently identified in patients with severe COVID-19. These initial COVID-19 autopsy studies have afforded valuable insight into the pathophysiology of this disease; however, only a limited number of case series have focused on lymphoid or haematopoietic tissues.

Methods: BM and lymph node (LN) specimens were obtained from adult autopsies performed between 1 April 2020 and 1 June 2020, for which the decedent had tested positive for SARS-CoV-2. Tissue sections (H&E, CD3, CD20, CD21, CD138, CD163, MUM1, kappa/lambda light chains in situ hybridisation) were examined by two haematopathologists, who recorded morphological features in a blinded fashion. Haemophagocytic lymphohistiocytosis (HLH) was assessed based on HLH 2004 criteria.

Results: The BM demonstrated a haemophagocytic pattern in 9 out of 25 patients (36%). The HLH pattern was associated with longer hospitalisation, BM plasmacytosis, LN follicular hyperplasia and lower aspartate aminotransferase (AST), as well as ferritin at demise. LN examination showed increased plasmacytoid cells in 20 of 25 patients (80%). This pattern was associated with a low absolute monocyte count at diagnosis, lower white cell count and lower absolute neutrophil count at demise, and lower ferritin and AST at demise.

Conclusions: Autopsy results demonstrate distinct morphological patterns in BM, with or without haemophagocytic macrophages, and in LN, with or without increased plasmacytoid cells. Since only a minority of patients met diagnostic criteria for HLH, the observed BM haemophagocytic macrophages may be more indicative of an overall inflammatory state.

目的:在重症 COVID-19 患者的骨髓(BM)中反复发现嗜血细胞增多症。这些最初的 COVID-19 尸检研究为了解该病的病理生理学提供了宝贵的资料;然而,只有少数病例系列研究侧重于淋巴组织或造血组织:从 2020 年 4 月 1 日至 2020 年 6 月 1 日期间进行的成人尸体解剖中获取骨髓和淋巴结标本,死者的 SARS-CoV-2 检测呈阳性。组织切片(H&E、CD3、CD20、CD21、CD138、CD163、MUM1、kappa/lambda 轻链原位杂交)由两名血液病理学家检查,他们以盲法记录形态特征。嗜血细胞性淋巴组织细胞增多症(HLH)是根据 HLH 2004 标准进行评估的:结果:25 名患者中有 9 人(36%)的生化组织显示出噬血细胞模式。HLH模式与住院时间较长、BM浆细胞增多、LN滤泡增生、较低的天冬氨酸氨基转移酶(AST)以及死亡时的铁蛋白有关。LN 检查显示,25 名患者中有 20 人(80%)的浆细胞增多。这种模式与诊断时单核细胞绝对计数较低、死亡时白细胞计数和中性粒细胞绝对计数较低、死亡时铁蛋白和谷草转氨酶较低有关:尸检结果表明,骨髓和淋巴结的形态模式各不相同,前者有或没有嗜血细胞巨噬细胞,后者有或没有浆细胞增多。由于只有少数患者符合 HLH 的诊断标准,因此观察到的 BM 嗜血细胞巨噬细胞可能更能说明整体炎症状态。
{"title":"Autopsy findings from patients diagnosed with COVID-19 demonstrate unique morphological patterns in bone marrow and lymph node.","authors":"Ali AlJabban, Mark G Evans, Geoffrey G Fell, Jack P Guccione, Robert A Edwards, Geraldine S Pinkus, Robert F Padera, Olga Pozdnyakova, Annette S Kim","doi":"10.1136/jcp-2023-208875","DOIUrl":"10.1136/jcp-2023-208875","url":null,"abstract":"<p><strong>Aims: </strong>The identification of haemophagocytosis in bone marrow (BM) is recurrently identified in patients with severe COVID-19. These initial COVID-19 autopsy studies have afforded valuable insight into the pathophysiology of this disease; however, only a limited number of case series have focused on lymphoid or haematopoietic tissues.</p><p><strong>Methods: </strong>BM and lymph node (LN) specimens were obtained from adult autopsies performed between 1 April 2020 and 1 June 2020, for which the decedent had tested positive for SARS-CoV-2. Tissue sections (H&E, CD3, CD20, CD21, CD138, CD163, MUM1, kappa/lambda light chains in situ hybridisation) were examined by two haematopathologists, who recorded morphological features in a blinded fashion. Haemophagocytic lymphohistiocytosis (HLH) was assessed based on HLH 2004 criteria.</p><p><strong>Results: </strong>The BM demonstrated a haemophagocytic pattern in 9 out of 25 patients (36%). The HLH pattern was associated with longer hospitalisation, BM plasmacytosis, LN follicular hyperplasia and lower aspartate aminotransferase (AST), as well as ferritin at demise. LN examination showed increased plasmacytoid cells in 20 of 25 patients (80%). This pattern was associated with a low absolute monocyte count at diagnosis, lower white cell count and lower absolute neutrophil count at demise, and lower ferritin and AST at demise.</p><p><strong>Conclusions: </strong>Autopsy results demonstrate distinct morphological patterns in BM, with or without haemophagocytic macrophages, and in LN, with or without increased plasmacytoid cells. Since only a minority of patients met diagnostic criteria for HLH, the observed BM haemophagocytic macrophages may be more indicative of an overall inflammatory state.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"622-627"},"PeriodicalIF":2.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9967395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How many mislabelled samples go unidentified? Results of a pilot study to determine the occult mislabelled sample rate. 有多少贴错标签的样本未被发现?一项旨在确定隐性误标样本率的试点研究结果。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-08-16 DOI: 10.1136/jcp-2024-209544
Caitlin Raymond, Liesel Dell'Osso, David Guerra, Julia Hernandez, Leonel Rendon, Donna Fuller, Alejandro Villasante-Tezanos, JuanDavid Garcia, Peter McCaffrey, Christopher Zahner

Background: Specimens with incorrect patient information are both a critical safety error and difficult to identify. Estimates of sample mislabelling rely on subjective identification of mislabelling, with the possibility that not all mislabelled samples are being caught.

Methods: We determined the blood type of two or more complete blood count specimens with the same patient label and assessed for discrepancies. We additionally determined the rate of identified sample mislabelling for the study period.

Results: We found a rate of 3.17 per 1000 discrepancies over the study period. These discrepancies most likely represent occult, or unidentified, mislabelled samples. In contrast, the rate of identified sample mislabelling was 1.15 per 1000.

Conclusions: This study suggests that specimens identified as, or known to be, mislabelled represent only a fraction of those mislabelled. These findings are currently being confirmed in our laboratory and are likely generalisable to other institutions.

背景:患者信息有误的样本既是严重的安全错误,又很难识别。对样本错误标注的估计依赖于对错误标注的主观识别,可能并非所有错误标注的样本都被发现:方法:我们对带有相同患者标签的两份或多份全血细胞计数样本进行血型鉴定,并评估是否存在差异。此外,我们还确定了研究期间已确认的样本误标率:结果:在研究期间,我们发现每 1000 份样本中有 3.17 份存在差异。这些差异很可能是隐性或未识别的错误标签样本。与此形成对比的是,已识别样本的误标率为 1.15‰:这项研究表明,被确认为或已知被贴错标签的样本只占贴错标签样本的一小部分。这些发现目前正在我们的实验室得到证实,并有可能推广到其他机构。
{"title":"How many mislabelled samples go unidentified? Results of a pilot study to determine the occult mislabelled sample rate.","authors":"Caitlin Raymond, Liesel Dell'Osso, David Guerra, Julia Hernandez, Leonel Rendon, Donna Fuller, Alejandro Villasante-Tezanos, JuanDavid Garcia, Peter McCaffrey, Christopher Zahner","doi":"10.1136/jcp-2024-209544","DOIUrl":"10.1136/jcp-2024-209544","url":null,"abstract":"<p><strong>Background: </strong>Specimens with incorrect patient information are both a critical safety error and difficult to identify. Estimates of sample mislabelling rely on subjective identification of mislabelling, with the possibility that not all mislabelled samples are being caught.</p><p><strong>Methods: </strong>We determined the blood type of two or more complete blood count specimens with the same patient label and assessed for discrepancies. We additionally determined the rate of identified sample mislabelling for the study period.</p><p><strong>Results: </strong>We found a rate of 3.17 per 1000 discrepancies over the study period. These discrepancies most likely represent occult, or unidentified, mislabelled samples. In contrast, the rate of identified sample mislabelling was 1.15 per 1000.</p><p><strong>Conclusions: </strong>This study suggests that specimens identified as, or known to be, mislabelled represent only a fraction of those mislabelled. These findings are currently being confirmed in our laboratory and are likely generalisable to other institutions.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"647-650"},"PeriodicalIF":2.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enteroblastic gastric cancer subtype holds therapeutic clues. 肠细胞性胃癌亚型蕴含治疗线索
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-08-16 DOI: 10.1136/jcp-2023-209346
Vikram Deshpande, Munita Bal
{"title":"Enteroblastic gastric cancer subtype holds therapeutic clues.","authors":"Vikram Deshpande, Munita Bal","doi":"10.1136/jcp-2023-209346","DOIUrl":"10.1136/jcp-2023-209346","url":null,"abstract":"","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"605-607"},"PeriodicalIF":2.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Learning at a distance: results of an international survey on the adoption of virtual conferences and whole slide imaging by pathologists. 远程学习:病理学家采用虚拟会议和全切片成像技术的国际调查结果。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-08-16 DOI: 10.1136/jcp-2023-208912
Thiyaphat Laohawetwanit, Raul S Gonzalez, Andrey Bychkov

Aims: This study presents the findings of a global survey of pathologists' views of online conferences and digital pathology.

Methods: An online anonymous survey consisting of 11 questions focusing on pathologists' perceptions of virtual conferences and digital slides was distributed to practising pathologists and trainees across the globe using the authors' social media accounts and professional society connections. Participants were asked to rank their preference for various aspects of pathology meetings on a 5-point Likert scale.

Results: There were 562 respondents from 79 countries. Several advantages of virtual meetings were recognised, including that they are less expensive to attend than in-person meetings (mean 4.4), more convenient to attend remotely (mean 4.3) and more efficient due to no loss of time for travel (mean 4.3). The lack of networking was reported as the main disadvantage of virtual conferences (mean 4.0). Most respondents (n=450, 80.1%) preferred hybrid or virtual meetings. About two-thirds (n=356, 63.3%) had no concern regarding the use of virtual slides for educational purposes and viewed them as an acceptable substitute for glass slides.

Conclusions: Online meetings and whole slide imaging are viewed as valuable tools in pathology education. Virtual conferences allow affordable registration fees and flexibility for participants. However, networking opportunities are limited, meaning in-person meetings cannot be entirely replaced by virtual conferences. Hybrid meetings may be a solution to maximise the benefits of both virtual and in-person meetings.

目的:本研究介绍了病理学家对在线会议和数字病理学看法的全球调查结果:利用作者的社交媒体账户和专业协会关系,向全球在职病理学家和受训人员分发了一份在线匿名调查,其中包括 11 个问题,重点是病理学家对虚拟会议和数字幻灯片的看法。参与者被要求用 5 点李克特量表对他们对病理会议各个方面的偏好进行排序:结果:共有来自 79 个国家的 562 名受访者。虚拟会议的几个优点得到了认可,其中包括参加会议的费用比现场会议低(平均值为 4.4),远程参加会议更方便(平均值为 4.3),由于不耽误旅行时间,因此效率更高(平均值为 4.3)。据报告,缺乏网络联系是虚拟会议的主要缺点(平均值为 4.0)。大多数受访者(n=450,80.1%)倾向于混合会议或虚拟会议。约三分之二的受访者(n=356,63.3%)对将虚拟幻灯片用于教育目的没有顾虑,并认为虚拟幻灯片是可以接受的玻璃幻灯片替代品:结论:在线会议和全切片成像被视为病理学教育的重要工具。虚拟会议为与会者提供了实惠的注册费和灵活性。然而,建立联系的机会有限,这意味着虚拟会议不能完全取代面对面会议。混合会议可能是一种解决方案,可最大限度地发挥虚拟会议和现场会议的优势。
{"title":"Learning at a distance: results of an international survey on the adoption of virtual conferences and whole slide imaging by pathologists.","authors":"Thiyaphat Laohawetwanit, Raul S Gonzalez, Andrey Bychkov","doi":"10.1136/jcp-2023-208912","DOIUrl":"10.1136/jcp-2023-208912","url":null,"abstract":"<p><strong>Aims: </strong>This study presents the findings of a global survey of pathologists' views of online conferences and digital pathology.</p><p><strong>Methods: </strong>An online anonymous survey consisting of 11 questions focusing on pathologists' perceptions of virtual conferences and digital slides was distributed to practising pathologists and trainees across the globe using the authors' social media accounts and professional society connections. Participants were asked to rank their preference for various aspects of pathology meetings on a 5-point Likert scale.</p><p><strong>Results: </strong>There were 562 respondents from 79 countries. Several advantages of virtual meetings were recognised, including that they are less expensive to attend than in-person meetings (mean 4.4), more convenient to attend remotely (mean 4.3) and more efficient due to no loss of time for travel (mean 4.3). The lack of networking was reported as the main disadvantage of virtual conferences (mean 4.0). Most respondents (n=450, 80.1%) preferred hybrid or virtual meetings. About two-thirds (n=356, 63.3%) had no concern regarding the use of virtual slides for educational purposes and viewed them as an acceptable substitute for glass slides.</p><p><strong>Conclusions: </strong>Online meetings and whole slide imaging are viewed as valuable tools in pathology education. Virtual conferences allow affordable registration fees and flexibility for participants. However, networking opportunities are limited, meaning in-person meetings cannot be entirely replaced by virtual conferences. Hybrid meetings may be a solution to maximise the benefits of both virtual and in-person meetings.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"632-638"},"PeriodicalIF":2.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9482862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HER2/ERBB2 overexpression in advanced gallbladder carcinoma: comprehensive evaluation by immunocytochemistry and fluorescence in situ hybridisation on fine-needle aspiration cytology samples. 晚期胆囊癌中的 HER2/ERBB2 过度表达:通过免疫细胞化学和荧光原位杂交对细针穿刺细胞学样本进行综合评估。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-08-16 DOI: 10.1136/jcp-2023-208940
Pragya Verma, Parikshaa Gupta, Nalini Gupta, Radhika Srinivasan, Pankaj Gupta, Usha Dutta, Shelly Sharma, Radha Uppal, Ritambhra Nada, Anupam Lal

Aims: Advanced gallbladder carcinoma (AGBC) carries a poor prognosis with dismal survival. There are no data regarding HER2/ERBB2 expression in AGBC. This study evaluated the overexpression of HER2/ERBB2 in cytological aspirates from AGBCs to identify potential patients for whom anti-HER2 targeted therapies can benefit.

Methods: This prospective, case-control study was performed on 50 primary AGBC cases. A detailed cytomorphological assessment, followed by immunocytochemistry (ICC) for HER2/ERBB2, was performed on AGBC cell blocks. A similar number of age-matched and gender-matched resected chronic cholecystitis specimens were included as controls. Fluorescence in situ hybridisation (FISH) was performed in equivocal cases.

Results: A total of 10 (20%) cases showed positive (3+), 19 (38%) equivocal (2+) expression and 21 (42%) were negative on HER2/ERBB2 ICC. None of the equivocal cases demonstrated HER2 amplification by FISH. Among the controls, none showed positive (3+) immunoexpression, 23 (46%) demonstrated equivocal expression and 27 (54%) were negative. On statistical analysis, HER2/ERBB2 overexpression was significantly associated with AGBC compared with the controls. Of all the clinical, radiological and cytomorphological parameters, the predominant papillary or acinar arrangements of the tumour cells were significantly associated with HER2/ERBB2 overexpression.

Conclusions: This is the first study to evaluate the expression of HER2/ERBB2 on cytological aspirates in AGBC using ICC and FISH. HER2/ERBB2 overexpression(20%) was significantly associated with AGBC. Furthermore, predominant papillary or acinar arrangements of tumour cells in the cytological smears were significantly associated with HER2/ERBB2 overexpression. They can serve as potential predictors of HER2/ERBB2 overexpression to select AGBC patients for anti-HER2 targeted therapies.

目的:晚期胆囊癌(AGBC)预后不良,生存率低。目前还没有关于HER2/ERBB2在AGBC中表达的数据。本研究评估了HER2/ERBB2在AGBC细胞学抽吸物中的过表达情况,以确定抗HER2靶向疗法可惠及的潜在患者:这项前瞻性病例对照研究针对50例原发性AGBC病例。对AGBC细胞块进行了详细的细胞形态学评估,随后进行了HER2/ERBB2免疫细胞化学(ICC)检测。同样数量的年龄和性别匹配的慢性胆囊炎切除标本作为对照。对不确定的病例进行荧光原位杂交(FISH):结果:共有 10 例(20%)HER2/ERBB2 ICC 表达阳性(3+),19 例(38%)表达不明确(2+),21 例(42%)阴性。在表达不明确的病例中,没有一个通过 FISH 检测出 HER2 扩增。在对照组中,无一例出现阳性(3+)免疫表达,23 例(46%)表达不明确,27 例(54%)为阴性。经统计分析,与对照组相比,HER2/ERBB2过表达与AGBC明显相关。在所有临床、放射学和细胞形态学参数中,肿瘤细胞主要呈乳头状或针状排列与HER2/ERBB2过表达明显相关:这是首次使用 ICC 和 FISH 评估 HER2/ERBB2 在 AGBC 细胞学抽吸物上的表达的研究。HER2/ERBB2过表达(20%)与AGBC明显相关。此外,细胞学涂片中肿瘤细胞主要呈乳头状或针状排列与HER2/ERBB2过表达有显著相关性。它们可作为HER2/ERBB2过表达的潜在预测指标,用于选择AGBC患者接受抗HER2靶向治疗。
{"title":"HER2/ERBB2 overexpression in advanced gallbladder carcinoma: comprehensive evaluation by immunocytochemistry and fluorescence in situ hybridisation on fine-needle aspiration cytology samples.","authors":"Pragya Verma, Parikshaa Gupta, Nalini Gupta, Radhika Srinivasan, Pankaj Gupta, Usha Dutta, Shelly Sharma, Radha Uppal, Ritambhra Nada, Anupam Lal","doi":"10.1136/jcp-2023-208940","DOIUrl":"10.1136/jcp-2023-208940","url":null,"abstract":"<p><strong>Aims: </strong>Advanced gallbladder carcinoma (AGBC) carries a poor prognosis with dismal survival. There are no data regarding HER2/ERBB2 expression in AGBC. This study evaluated the overexpression of HER2/ERBB2 in cytological aspirates from AGBCs to identify potential patients for whom anti-HER2 targeted therapies can benefit.</p><p><strong>Methods: </strong>This prospective, case-control study was performed on 50 primary AGBC cases. A detailed cytomorphological assessment, followed by immunocytochemistry (ICC) for HER2/ERBB2, was performed on AGBC cell blocks. A similar number of age-matched and gender-matched resected chronic cholecystitis specimens were included as controls. Fluorescence in situ hybridisation (FISH) was performed in equivocal cases.</p><p><strong>Results: </strong>A total of 10 (20%) cases showed positive (3+), 19 (38%) equivocal (2+) expression and 21 (42%) were negative on HER2/ERBB2 ICC. None of the equivocal cases demonstrated HER2 amplification by FISH. Among the controls, none showed positive (3+) immunoexpression, 23 (46%) demonstrated equivocal expression and 27 (54%) were negative. On statistical analysis, HER2/ERBB2 overexpression was significantly associated with AGBC compared with the controls. Of all the clinical, radiological and cytomorphological parameters, the predominant papillary or acinar arrangements of the tumour cells were significantly associated with HER2/ERBB2 overexpression.</p><p><strong>Conclusions: </strong>This is the first study to evaluate the expression of HER2/ERBB2 on cytological aspirates in AGBC using ICC and FISH. HER2/ERBB2 overexpression(20%) was significantly associated with AGBC. Furthermore, predominant papillary or acinar arrangements of tumour cells in the cytological smears were significantly associated with HER2/ERBB2 overexpression. They can serve as potential predictors of HER2/ERBB2 overexpression to select AGBC patients for anti-HER2 targeted therapies.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"614-621"},"PeriodicalIF":2.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9512291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accuracy and validity of determined cause of death and manner of death following forensic autopsy prosection. 法医解剖后确定死因和死亡方式的准确性和有效性。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-08-16 DOI: 10.1136/jcp-2023-208876
Armaan Shergill, Peter Conner, Machelle Wilson, Bennet Omalu

Aims: The purpose of this study is to evaluate the accuracy and validity of the determination of cause of death (COD) and manner of death (MOD) at the completion of the forensic autopsy prosection.

Methods: We analysed 952 autopsy cases conducted from 2019 to 2020 and compared every patient's COD, other significant contributing factors to death (OSC), and MOD after prosection to their COD, OSC and MOD after completion of the final autopsy report.

Results: We found that 83% of cases (790 patients) did not have an unexpected change and 17% of cases (162 patients) exhibited a true change in their final diagnosis; the relationship between age and changes in COD and MOD was significant.

Conclusions: Our findings indicate that in the majority of forensic autopsy cases, medical professionals can reasonably complete death certification after the autopsy prosection. In addition to improving the accuracy of COD and MOD, advances in this field will enhance timely decedent affairs management, timely investigations of crimes and timely closure to families who have lost loved ones. We recommend implementing combined interventional education and consultation with expert pathologists, and a well-followed structured method of death classification as the best course of practice.

目的:本研究旨在评估法医尸检解剖完成后确定死因(COD)和死亡方式(MOD)的准确性和有效性:我们分析了 2019 年至 2020 年期间进行的 952 例尸检病例,并将每位患者在尸检后的死因、其他重要死亡诱因(OSC)和死亡方式与最终尸检报告完成后的死因、OSC 和死亡方式进行了比较:我们发现,83%的病例(790 名患者)的最终诊断没有发生意外变化,17%的病例(162 名患者)的最终诊断发生了真正的变化;年龄与 COD 和 MOD 变化之间的关系显著:我们的研究结果表明,在大多数法医尸检病例中,医务人员可以在尸检解剖后合理地完成死亡证明。除了提高COD和MOD的准确性外,这一领域的进步还将加强对死者事务的及时处理、对犯罪的及时调查以及对失去亲人的家庭的及时补偿。我们建议将干预性教育与病理专家的咨询相结合,并采用结构化的死亡分类方法,以此作为最佳实践方案。
{"title":"Accuracy and validity of determined cause of death and manner of death following forensic autopsy prosection.","authors":"Armaan Shergill, Peter Conner, Machelle Wilson, Bennet Omalu","doi":"10.1136/jcp-2023-208876","DOIUrl":"10.1136/jcp-2023-208876","url":null,"abstract":"<p><strong>Aims: </strong>The purpose of this study is to evaluate the accuracy and validity of the determination of cause of death (COD) and manner of death (MOD) at the completion of the forensic autopsy prosection.</p><p><strong>Methods: </strong>We analysed 952 autopsy cases conducted from 2019 to 2020 and compared every patient's COD, other significant contributing factors to death (OSC), and MOD after prosection to their COD, OSC and MOD after completion of the final autopsy report.</p><p><strong>Results: </strong>We found that 83% of cases (790 patients) did not have an unexpected change and 17% of cases (162 patients) exhibited a true change in their final diagnosis; the relationship between age and changes in COD and MOD was significant.</p><p><strong>Conclusions: </strong>Our findings indicate that in the majority of forensic autopsy cases, medical professionals can reasonably complete death certification after the autopsy prosection. In addition to improving the accuracy of COD and MOD, advances in this field will enhance timely decedent affairs management, timely investigations of crimes and timely closure to families who have lost loved ones. We recommend implementing combined interventional education and consultation with expert pathologists, and a well-followed structured method of death classification as the best course of practice.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"628-631"},"PeriodicalIF":2.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11347210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9622280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sudden cardiac death with morphologically normal heart: always do toxicology. 心脏形态正常的心脏性猝死:一定要做毒理学检查。
IF 2.5 4区 医学 Q2 PATHOLOGY Pub Date : 2024-08-16 DOI: 10.1136/jcp-2023-209351
Davide Radaelli, Joseph Westaby, Gherardo Finocchiaro, Gianfranco Sinagra, Stefano D'Errico, Mary N Sheppard
{"title":"Sudden cardiac death with morphologically normal heart: always do toxicology.","authors":"Davide Radaelli, Joseph Westaby, Gherardo Finocchiaro, Gianfranco Sinagra, Stefano D'Errico, Mary N Sheppard","doi":"10.1136/jcp-2023-209351","DOIUrl":"10.1136/jcp-2023-209351","url":null,"abstract":"","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"645-646"},"PeriodicalIF":2.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11347233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140158179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Pathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1